The Diagnostic Roadmap and Cancer Screening

The process of diagnosing paraneoplastic polyneuropathy (PPN) is often called a “tumor hunt” because the nerve symptoms are frequently the first—and sometimes only—sign that a small cancer is present. Because these tumors can be hidden, doctors use clinical assessment and a specific roadmap called the 2021 PNS-Care criteria to determine how likely it is that your symptoms are caused by cancer ^[1].

Diagnostic Core Evaluation

A comprehensive diagnostic evaluation involves excluding common mimics of nerve disease. Your medical team will typically utilize:

• Neurological Examination: To evaluate specific patterns of weakness, numbness, and balance.
• EMG/Nerve-Conduction Studies: Electrical testing to map out nerve damage.
• Selected MRI and CSF Studies: To rule out direct cancer involvement or structural causes.
• Laboratory Evaluation: To evaluate for mimics such as diabetes, B12 deficiency, paraproteinemia, Sjögren’s disease, or medication toxicities.
• Expert Antibody Testing: Blood and/or spinal fluid analysis.

The 2021 Diagnostic Framework

The 2021 criteria use a scoring system to classify your condition as Possible, Probable, or Definite paraneoplastic syndrome ^[1][2].

• What these labels mean: These categories describe the clinician’s diagnostic confidence in the link to cancer. They are not a prediction of your personal disease severity or the stage of an actual tumor ^[1].
• How it is determined: The score relies on three main factors:
  1. Clinical Phenotype: Certain patterns of nerve damage, like subacute sensory neuronopathy (loss of balance and patchy numbness), are considered “High-Risk” because they are frequently linked to cancer ^[3][4].
  2. Antibody Type: “High-Risk” antibodies (like Anti-Hu or CV2/CRMP5) are associated with cancer in more than 70% of cases ^[1].
  3. Cancer Status: Whether a matching tumor has been found ^[1][5].

Testing Both Blood and Spinal Fluid

Testing both your blood (serum) and cerebrospinal fluid (CSF) can be useful for obtaining an accurate diagnosis ^[3]. Assay sensitivity differs, and unexpected or low-titer results should be reviewed in an expert neuroimmunology laboratory ^[6]. While confirmatory testing with different methods is standard practice to prevent false-positives, urgent clinical decisions should not be unnecessarily delayed while waiting for confirmation ^[7][8].

The Imaging Pathway

If your doctors suspect PPN, they will tailor an imaging protocol to find the trigger:

• Targeted Imaging: This usually begins with a high-quality CT scan of the chest, abdomen, and pelvis ^[9]. Depending on your antibody, age, and sex, targeted screenings like mammography, breast MRI, or testicular/pelvic ultrasound may be more appropriate ^[10].
• Whole-Body FDG-PET/CT: If the initial scans are negative or unclear, the next step is often a PET scan ^[11]. This scan identifies areas of high metabolic activity. Note that PET does not diagnose cancer on its own; suspicious findings may require targeted biopsy, and false positives are possible ^[12][13].

Long-Term Vigilance

One of the most challenging aspects of PPN is that the immune system can react to a tumor long before it is large enough to see on a scan ^[14]. For this reason, if you have a High-Risk antibody but the initial search is negative, international guidelines recommend a personalized plan of continued cancer screening ^[1][7].

Depending on your individual risk factors, expert consensus may suggest repeating cancer screenings for several years ^[10]. Your medical team will help balance the necessity of finding a tumor against the radiation exposure, contrast risks, and anxiety of repeated testing ^[15].